Larazotide acetate is one of the furthest-along drug candidates aimed specifically at celiac disease, a condition that currently has no FDA-approved medication of its own. It's a peptide, but an unusual one: rather than circulating through the bloodstream like a GLP-1 drug, it's designed to act locally in the gut and barely be absorbed at all.
What It Is
Larazotide acetate is a synthetic eight-amino-acid peptide originally developed by Alba Therapeutics and later advanced by Innovate Biopharmaceuticals through its clinical program. It's designed as a "tight junction regulator," meaning it targets the protein structures that hold the cells lining the small intestine closely together.
The Problem It's Trying to Solve
In celiac disease, exposure to gluten triggers an immune response that, among other things, loosens those tight junctions, a condition often described as increased intestinal permeability. That allows larger food fragments and other molecules to cross the gut lining more easily than they should, which researchers believe contributes to the broader immune and inflammatory cascade that causes celiac symptoms and intestinal damage. Larazotide's proposed mechanism is to help keep those junctions closed even during gluten exposure, functioning as a kind of barrier reinforcement rather than a treatment that suppresses the immune system directly.
Where It Stands in Development
Larazotide has gone through multiple Phase 2 trials and at least one Phase 3 program over more than a decade of development, with results across that history that have been mixed: some trials met their primary endpoint for reducing symptoms during gluten exposure, while others did not, which is part of why the drug has changed hands between sponsors over the years. It is not FDA-approved and is not available by prescription or over the counter for celiac disease or any other condition. Anyone encountering larazotide marketed outside a registered clinical trial should treat that as a red flag, since there is no legitimate commercial source for it at this time.
What the Human Evidence Shows
Unlike many of the research-chemical peptides covered elsewhere on this site, larazotide's evidence base is built almost entirely on controlled human clinical trials rather than animal studies, simply because its trial program has been running for years in actual celiac patients. That's a meaningfully different evidence profile from a compound like BPC-157. Even so, having reached Phase 3 trials is not the same as being approved or proven effective, and the mixed trial results to date mean the case for larazotide's efficacy remains unresolved rather than established.
What It Is Not
Larazotide is not a treatment that would let someone with celiac disease eat gluten freely; even in the most optimistic framing from its developers, it has been studied as an adjunct to an existing gluten-free diet, intended to blunt symptoms from accidental gluten exposure rather than replace dietary management. It's also unrelated to the gut-healing claims made for compounds like BPC-157, despite both being discussed in a gastrointestinal context; the proposed mechanisms, evidence bases, and regulatory situations are entirely different.
The Bottom Line
Larazotide acetate represents a genuinely different category from most peptides covered on this site: a non-systemic, gut-localized peptide drug candidate with a real, if uneven, Phase 2 and Phase 3 human trial record behind it. It is still unapproved, and people managing celiac disease should continue following their physician's or dietitian's guidance on gluten-free diet management rather than anticipating a specific approval timeline. Anyone with questions about celiac disease treatment options should talk to a gastroenterologist.